Introduct ion

Response:
We agree that a focus on previous metaanalyses in the field is very important. To our knowledge we have referred to the few existing relevant previous meta-analysis (references 21-24) . In response to the remarks on unnecessary details in the introduction section we have shortened the manuscript as follows:
Manuscript change 1: Page 5 line 9: -Early-onset schizophrenia (EOS) We agree with the reviewers comments that the typical reader of BMJ Open is probably not that experienced statistics and the implications of meta-analyses (incl. the recent extension to a network MA).
Reviewer #2 raise an important point "why it is important to publish a meta-analysis protocol". Although protocol registration and subsequent registration for meta-analyses is still not common practice, these "pre-specifications" will increase the awareness of the "prospective part" of a (retrospective) Response: Contact with pharmaceutical companies: The authors of this meta-analysis follow the rules of full disclosure of potential conflicts of interest to be transparent. However, the fact that experts interact with a number of pharmaceutical companies does not inherently signify a bias of their work. Presence or absence of such bias will need to be evaluated based on the submitted work that is produced in close collaboration with the other authors who do not have any relationship with the pharmaceutical industry. Moreover, potential biases are by no means restricted to interacting with the pharmaceutical industry, and these other potential biases are generally not disclosed, precluding open evaluation for presence of a potential influence on the work.
